News

Exposure to a chemical found in a wide variety of consumer products may trigger the growth of uterine fibroid cells and delay the rate at which they die, suggests a study funded by the National Institutes of Health. The study provides a potential explanation for why women exposed to industrial chemicals known as phthalates—found in personal care products, food packaging, and medical products—have higher rates of fibroid tumors than other women. The findings may also inform future strategies to prevent or treat fibroids.

Patterns of gene expression—the degree to which genes are turned on or off—in uterine muscle tissue may help explain why fibroids disproportionately affect Black women, suggests a study supported by NICHD. Understanding the factors that contribute to racial disparities in uterine fibroid disease can inform treatment and prevention approaches.

Researchers funded by the National Institutes of Health have developed a prototype genetic test with the potential to predict the development and eventual severity of uterine fibroids—benign, but sometimes painful and debilitating tumors of the uterus. The test could be used to identify fibroid cases early and to better understand how they develop and how to treat them.

Read about NICHD’s research findings and activities from 2021.

Among American Black and white women, the risk and extent of fibroids—benign tumors of the uterus—are associated with ancestry to distinct regions and populations, suggests a study funded by the National Institutes of Health. The study provides information that may lead to insights on the origins and treatments for these common tumors.

Read about NICHD’s research findings and activities from 2020.

NICHD has supported gynecologic and reproductive health research for decades. Learn more about its leading role in menstruation research.

In a study of mice, NIH-funded researchers have developed a prototype technique for shrinking uterine fibroids—sometimes painful, noncancerous tumors that form in the uterus. The method involves encasing a tumor-killing drug in nano-sized spheres called liposomes and delivering them directly to the fibroids through the bloodstream. The findings set the stage for studies to determine if the method is safe and effective for treating fibroids in people.

In an editorial, Diana W. Bianchi, M.D., NICHD Director and Matthew W. Gillman, M.D., S.M., emphasize that women and children bear a substantial burden of the U.S. opioid epidemic and that coordinated, long-term research is essential to filling knowledge gaps about how opioids affect women and children.

Dr. Candace Tingen with NICHD’s Gynecological Health and Disease Branch speaks about the possibilities of tapping a woman’s menstrual cycle for signs of disease. Listen to our latest podcast.

The Gynecologic Health and Disease Branch recently published its scientific vision. The document summarizes its research themes, which provide direction for future research.